MuPeXI: prediction of neo-epitopes from tumor sequencing data
- 2k Downloads
Personalization of immunotherapies such as cancer vaccines and adoptive T cell therapy depends on identification of patient-specific neo-epitopes that can be specifically targeted. MuPeXI, the mutant peptide extractor and informer, is a program to identify tumor-specific peptides and assess their potential to be neo-epitopes. The program input is a file with somatic mutation calls, a list of HLA types, and optionally a gene expression profile. The output is a table with all tumor-specific peptides derived from nucleotide substitutions, insertions, and deletions, along with comprehensive annotation, including HLA binding and similarity to normal peptides. The peptides are sorted according to a priority score which is intended to roughly predict immunogenicity. We applied MuPeXI to three tumors for which predicted MHC-binding peptides had been screened for T cell reactivity, and found that MuPeXI was able to prioritize immunogenic peptides with an area under the curve of 0.63. Compared to other available tools, MuPeXI provides more information and is easier to use. MuPeXI is available as stand-alone software and as a web server at http://www.cbs.dtu.dk/services/MuPeXI.
KeywordsNeo-epitopes Neo-antigens Immunotherapy Prediction Mutation Sequencing
Area under the curve
Mutant peptide extractor and informer
Next generation sequencing
Non-small cell lung cancer
Receiver operator characteristic
Single nucleotide variant
Variant call format
Variant effect predictor
Whole exome sequencing
We thank Charles Swanton and Nicholas McGranahan for providing the raw data from the two NSCLC studies; Sofie Ramskov, Rikke Lyngaa and Sunil Kumar Saini for their experimental work in these studies; Amalie Kai Bentzen for her contribution to methods development; and Thomas Trolle, Andrea Marquard and Marcin Krzystanek for helpful discussions.
This work was supported by the Danish Cancer Society under grant R72-A4618 (Aron Charles Eklund); the Novo Nordisk Foundation under Grant 16,854 (Zoltan Szallasi); the Breast Cancer Research Foundation (Zoltan Szallasi); and the Danish Council for Independent Research under Grant 1331-00283 (Sine Reker Hadrup, Zoltan Szallasi).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 13.Krueger F Trim Galore (2016) http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/. Accessed 19 Sep 2016
- 15.Andrews S FastQC (2016) http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. Accessed 19 Sep 2016